Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC
NCT06998719
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
80
Enrollment
OTHER
Sponsor class
Conditions
Non-small Cell Lung Cancer Stage III
Borderline Resectable Carcinoma
Interventions
DRUG:
Durvalumab
Sponsor
Bi Nan
Collaborators
[object Object]